AlphaTON Capital Corp (Nasdaq: ATON) and its wholly owned oncology subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics, today announced that a new poster is online at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. The work, conducted with researchers from the Italian Group for Mesothelioma (GIMe) and collaborators, provides the … Continue reading AlphaTON Capital and Cyncado Therapeutics Share New Mesothelioma Data Supporting TT-4’s Pathway to First Patient Delivery